一个新的PSEN2突变在缓解性早期阿尔茨海默病 (EOAD):一个家族病例系列
Carl Froilan D Leochico1,2,3,4,5, Ekaterina Rogaeva2,6, Ljubica Zotovic7
1Department of Psychiatry, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada.
Journal of Alzheimer's disease reports
|June 27, 2025
概括
在一个患有早期阿尔茨海默病 (EOAD) 的家庭中发现了一种新的PSEN2基因变异. 这种可能的致病变体与疾病分离,有助于了解痴呆的遗传原因.
科学领域:
- 遗传学 是一个遗传学.
- 神经学 神经学
- 分子生物学分子生物学
背景情况:
- 早期家族性阿尔茨海默氏症 (EOAD) 是一种罕见的痴呆症亚型.
- 在APP,PSEN1或PSEN2基因的自体主导突变是家族EOAD的常见原因.
研究的目的:
- 报告一种新型PSEN2误解变异 (c.359T>G,p.Ile120Ser),该变异在一个带有EOAD的家族中被发现.
- 在家族性EOAD的背景下,确定已识别的PSEN2变异的致病意义.
主要方法:
- 基因测序用于识别APP,PSEN1和PSEN2中的变异.
- 在受影响的家庭内进行隔离分析.
- 神经成像生物标记分析.
- 对PSEN2变种的生物信息分析.
主要成果:
- 在四个兄弟姐妹中发现了一种新的PSEN2误解变体 (p.Ile120Ser),其中三人患有amnestic EOAD或轻度认知障碍.
- 两个兄弟姐妹也对一种PSEN1变种 (p.Asp40del) 异构.
- 根据分离,成像数据和生物信息学预测,PSEN2变种被归类为可能致病的.
结论:
- 鉴定到的PSEN2变种很可能是致病性,并有助于家族性EOAD.
- 在家族EOAD病例中的遗传发现提高了对阿尔茨海默病病因的理解.
- 这项研究有助于对阿尔茨海默病遗传学中的致病变异进行分类.
更多相关视频
05:51A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia
Published on: June 15, 2011
26.0K
07:26High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
Published on: July 18, 2017
11.9K
相关概念视频
01:26Alzheimer's Disease: Overview
678
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
678
03:03Amyloid Fibrils
9.9K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.9K
01:22Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265